Dr. Ma has focused his research on pharmacotherapy of HIV-associated neurocognitive disorders. With a longer life expectancy, people living with long-term HIV infection exhibit clinical manifestations of aging early, such as multimorbidity, polypharmacy, and decline in cognitive abilities. Dr. Ma has developed a broad research program that has expanded and evolved into investigating pharmacokinetics and pharmacodynamics of antiretroviral therapy on the central nervous system, pharmacogenomics, drug-drug interactions, and polypharmacy in relation to neurocognitive function in the elderly living with HIV. His research projects involve a multidisciplinary team that encompasses pharmacy, clinical pharmacology, neurology, psychology, substance use disorders, and biomarker disciplines and utilize a variety of data and laboratory analytical techniques as well as cell culture and small animal models through collaborations.
Education and Training:
PharmD, University of Colorado (2017)
PhD, Loyola University Chicago (2003)
BS, West China University of Medical Sciences (1995)
Associate Professor of Pharmacy Practice, Pharmacy Practice, University at Buffalo (2019-present)
Adjunct Professor of Pharmacology and Physiology, University of Rochester (2012-present)
Research Scientist, Translational Pharmacology Research Core, University at Buffalo, New York State Center of Excellence in Bioinformatics and Life Sciences (2006-present)
Assistant Professor of Pharmacy Practice, Pharmacy Practice, University at Buffalo (2013–2019)
Research Assistant Professor, University at Buffalo (2006–2013)
Fellow, University at Buffalo (2004–2005)
Awards and Honors:
Research Mentor of the Year (2012)
Visiting Scholar (2010)
Visiting Professor (2008)
Conference Scholarship (2007)
George McCracken Infectious Disease Fellow (2005)
George McCracken Infectious Disease Fellow (2004)
Travel Award (2004)
Young Investigator Award (2003)
Graduate Travel Award (2002)
Grants and Sponsored Research:
June 2012–June 2017 Antiretroviral pharmacogenomics, pharmacokinetics and toxicity in neuroAIDS NIH Role: Principal Investigator $598,880
Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother. 2014.
Zhang L; Ma Q; Zhou H. Host proteome research in HIV infection.. 2010.
Liu X; Ma Q; Zhang F. Therapeutic drug monitoring in highly active antiretroviral therapy.. 2010.
Zhang R; Ma Q; Lu H. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.. 2009.
Lakhman SS; Ma Q; Morse ED. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics. 2009; 10.
McCabe SM; Ma Q; Slish J; Catanzaro LM; Sheth N; DiCenzo R; Morse ED. Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.. Clin Pharmacokinet. 2008; 47.
Cheang KI; Ma Q. Research in women and special populations. Pharmacotherapy. 2008; 28.
Ma Q; Forrest A; Rosenkranz SL; Para MF; Yarasheski KE; Reichman RC; Morse ED. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos. 2008; 29.
McCabe SM; Ma Q; Slish J; Catanzaro LM; Sheth N; DiCenzo R; Morse ED. Antiretroviral therapy: pharmacokinetic considerations in patients with renal or hepatic impairment. Clinical Pharmacokinetics. 2008; 47.
Ma Q; DiFrancesco R; Morse ED; Slish J; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau DA; Boston N; Catanzaro LM. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther Drug Monit. 2007; 29.
Ma Q; Brazeau DA; Forrest A; Morse ED. Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics. 2007; 8.
Maponga C; Ma Q; Slish J; Morse ED. HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries. Top HIV Med. 2007; 15.
McCabe SM; Smith PF; Ma Q; Morse ED. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol. 2007; 3.
Ma Q; Forrest A; Morse ED; Brazeau DA; Zingman BS; Reichman RC; Fischl MA; Gripshover BM; Venuto CS; Slish J; DiFrancesco R. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007; 8.
Mudzviti T; Maponga C; Khoza S; Tagwireyi D; Ma Q; Morse ED. Adverse Drug Reactions During Antiretroviral Therapy in Zimbabwe. 37th Annual International Conference on Global Health. 2010.
Maponga C; DiFrancesco R; Tooley KM; Jaravani P; Ma Q; Morse ED. Establishing an AIDS International Training and Research Program (AITRP) to Increase Capacity for HIV Clinical Pharmacology Research In Southern African Countries. 18th International AIDS Conference (AIDS 2010). 2010.
Venuto C; Ma Q; Morse ED. Effects of CYP2B6 single nucleotide polymorphism (SNPs) and substance abude on efavirenz (EFV) pharmacokinetics. UB Celebration of Academic Excellence. 2010.
Ma Q; Tooley KM; Welliver R; Condino D; Lliguicota F; Maponga C; DiFrancesco R; Morse ED; Sulaimen A; Felton C; Sawyer JR; Mudzviti T; Hsiao CB; Walshe K; Gbadamosi F; Sayidine F. Developing an International Health Information Technology Network for HIV Medication Management Research. NY HIV Research Centers Consortium. 2010.
Venuto C; Morse ED; Ma Q; Brazeau D; Zingman B; Reichman RC; Fischl M; Gripshover B; DiFrancesco R; Forrest A. Effects of CYP2B6 Single Nucleotide Polymorphisms (SNPs) and Substance Abuse on Efavirenz (EFV) Pharmacokinetics. ICAAC Conference. 2009.
Acheampong F; Morse ED; Ma Q; Brazeau D; Zingman B; Reichman R; Fischl M; Gripshover B; DiFrancesco R; Forrest A. Relationship between CYP3A5 Nucleotide Polymorphisms and Protease Inhibitor Trough Concentrations in HIV+ Patients during Therapeutic Drug Monitoring. ICAAC Conference. 2009.
Fehintola F; Ma Q; Zingman B; Reichman R; Fischl M; Gripshover B; DiFrancesco R; Forrest A; Morse ED. Tobacco and Marijuana Uses Significantly Decrease Atazanavir (ATV) Trough Concentrations in HIV Infected Individuals. ICAAC Conference. 2009.
Ma Q; Forrest A; Rosenkranz S; Para M; Adams E; Yaresheski K; Reichman RC; Morse ED; A. Optimal multidrug PK and sampling strategies (OSS) for efavirenz and indinavir. 2005 Annual Meeting of the American Society of Clinical Pharmacology & Therapeutics. 2005.
Zack J; A; Forrest A; Ma Q; Rosenkranz S; Para MF; Adams E; Yaresheski K; Reichman RC; Morse ED. Optimal Sparse Pharmacokinetic Sampling Strategies for Multi-Drug Antiretroviral Regimens. Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics. 2005.
International AIDS Society (2006)
American Society of Microbiology (2004)
Society of Infectious Diseases Pharmacists (2004)
American Society for Clinical Pharmacology and Therapeutics; Award Committee Member, Education Committee Member (2001)
American Society for Clinical Pharmacology and Therapeutics (2000–present)
American Pharmacist Association (1999)
"Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" XIX International AIDS Conference, IAS AIDS (2012)
"Tenofovir Plasma Pharmacokinetics in AIDS Clinical Trials Group Study A5202" XIX International AIDS Conference (AIDS/IAS 2012), IAS AIDS (2012)
"Comparison of modeled and non-modeled clearances for efeavirenz" Translational Science 2012 (2012)
"Pharmacogenomics of CYP3A: Considerations for HIV Treatment" 5th Health Disparities Conference, Xavier University of Louisiana (2012)
"A Physiological Pharmacokinetic Model Characterizes Efavirenz Metabolic Induction in HIV-Infected Ugandan Patients" 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (2011)
"Pharmacokinetics of efavirenz among HIV infected Ugandans" 12th International Workshop on Clinical Pharmacology of HIV Thearpy (2011)
"Establishing A Health Information Technology Network for HIV/TB Medication Management Research" 2nd Annual World AIDS Day Scientific Symposium, University of Rochester (2010)
"Interindividual Variability of ABCB1 Expression in Peripheral Blood Mononuclear Cells from HIV-Infected Patients" 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (2010)
"Developing an International Health Information Technology Network for HIV Medication Management Research" 2010 Scientific Conference New York HIV Research Centers Consortium (2010)
"Update on pharmacotherapy for pediatric HIV infection" 13th Asian Pacific Congress of Pediatrics (2009)
"Effects of CYP2B6 single nucleotide polymorphisms and substance abuse on efavirenz pharmacokinetics" 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM (2009)
"Inter-individual variability of atazanavir plasma concentrations in HIV patients" 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM (2009)
"Relationship between CYP3A5 single nucleotide polymorphisms and protease inhibitor trough concentrations in HIV+ patients during therapeutic drug monitoring" 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM (2009)
"Tobacco and marijuana uses significantly decrease atazanavir trough concentrations in HIV infected individuals" 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, ASM (2009)
"Comparison of antiretroviral pharmacokinetics and clinical monitoring parameters in HIV-infected patients with and without substance abuse" 16th Conference on Retroviruses and Opportunistic Infections (2009)
"Clinical and Translational Pharmacogenomics: Integrating a Seminar Program with UndergraduatePharmacogenomics Research" American College of Clinical Pharmacy 2008 Annual Meeting, American College of Clinical Pharmacy (2008)
"Determining the rate, nature and predictors of adverse drug reactions associated with the use of highly active antiretroviral therapy (HAART) in a resource limited setting (Zimbabwe)" IX World Conference on Clinical Pharmacology and Therapeutics (2008)
"Effect of CYP3A5 polymorphisms on atazanavir and lopinavir trough concentrations in HIV-infected substance abusers" 9th International Workshop on Clinical Pharmacology of HIV Therapy (2008)
"An Appropriate Structural and Population Pharmacokinetic (PK) Model for Atazanavir (ATV)" 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (2007)
"Therapeutic Drug Monitoring and Inhibitory Quotients in HIV-Infected Substance Users and Non-substance Users Receiving HIV-1 Protease Inhibitors" 14th Conference on Retroviruses and Opportunistic Infections (2007)
"CYP3A5 polymorphisms in HIV-infected substance users and nonusers during therapeutic drug monitoring" 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006)
"MDR1 Single Nucleotide Polymorphisms in HIV-infected Substance Users and Nonusers during Therapeutic Drug Monitoring" 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005)